Stealth BioTherapeutics Corp – NASDAQ:MITO

Add to watchlist

$0.32

Market closed

Open in 2 days

+1.59%

month

+2.89%

quarter

-68.32%

year

Market Cap	N/A
Enterprise value	N/A

P/E	-0.34
EV/Sales	N/A
EV/EBITDA	0.01
Price/Sales	N/A
Price/Book	-0.36
PEG ratio	-0.06
EPS	-0.95

Revenue	N/A
EBITDA	-51.49M
Income	-54.28M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Stealth BioTherapeutics Corp (NASDAQ:MITO): Profit margin
Jun 2021	0	-18.40M
Sep 2021	0	-6.29M
Dec 2021	0	-26.92M
Mar 2022	0	-2.65M

Stealth BioTherapeutics Corp (NASDAQ:MITO): Earnings per share (EPS)
2022-05-18	-0.02	-0.01

Stealth BioTherapeutics Corp (NASDAQ:MITO): Debt to assets
Jun 2021	32258000	58.57M	181.58%
Sep 2021	44187000	73.01M	165.25%
Dec 2021	50226000	95.52M	190.18%
Mar 2022	36915000	89.23M	241.72%

Stealth BioTherapeutics Corp (NASDAQ:MITO): Cash Flow
Jun 2020	0	0	0
Sep 2020	0	0	0
Dec 2020	-9.71M	-20K	22.63M
Dec 2021	-35.25M	203K	36.50M

Stealth BioTherapeutics Corp alternative data

Stealth BioTherapeutics Corp
Employees

Stealth BioTherapeutics Corp (NASDAQ:MITO): Employee count
Aug 2023	38
Sep 2023	38
Oct 2023	38
Nov 2023	38
Dec 2023	38
Jan 2024	38
Feb 2024	38
Mar 2024	38
Apr 2024	38
May 2024	38
Jun 2024	38
Jul 2024	38

Stealth BioTherapeutics Corp
Patents

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Methods for the regulation of matrix metalloproteinase expression Filling date: 2 Dec 2019 Issue date: 8 Mar 2022	2 Dec 2019	8 Mar 2022
Application	Application MITOCHONDRIA-TARGETING PEPTIDES Filling date: 19 Nov 2019 Issue date: 10 Feb 2022	19 Nov 2019	10 Feb 2022
Application	Application METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME Filling date: 9 Jul 2021 Issue date: 30 Dec 2021	9 Jul 2021	30 Dec 2021
Application	Application METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY Filling date: 16 Apr 2021 Issue date: 30 Dec 2021	16 Apr 2021	30 Dec 2021
Application	Application COMPOSITIONS AND METHODS FOR THE TREATMENT OF TRAUMATIC OPTIC NEUROPATHY Filling date: 15 Jul 2019 Issue date: 28 Oct 2021	15 Jul 2019	28 Oct 2021
Application	Application COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA Filling date: 2 Apr 2021 Issue date: 14 Oct 2021	2 Apr 2021	14 Oct 2021
Grant	Grant Utility: Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof Filling date: 17 Jan 2020 Issue date: 12 Oct 2021	17 Jan 2020	12 Oct 2021
Application	Application CRYSTALLINE SALT FORMS OF BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2 Filling date: 8 Apr 2021 Issue date: 23 Sep 2021	8 Apr 2021	23 Sep 2021
Grant	Grant Utility: Methods and compositions for the prevention or treatment of Barth Syndrome Filling date: 15 Jul 2020 Issue date: 10 Aug 2021	15 Jul 2020	10 Aug 2021
Grant	Grant Utility: Methods and compositions for the prevention or treatment of Barth Syndrome Filling date: 19 Jun 2017 Issue date: 10 Aug 2021	19 Jun 2017	10 Aug 2021

MITO patents

Stealth BioTherapeutics Corp
Earnings Call Transcripts

Quarter	Transcript
Q3 2021 11 Nov 2021	Q3 2021 Earnings Call Transcript
Q2 2021 7 Aug 2021	Q2 2021 Earnings Call Transcript
Q1 2021 18 May 2021	Q1 2021 Earnings Call Transcript
Q4 2020 6 Apr 2021	Q4 2020 Earnings Call Transcript

MITO earnings call transcripts

Stealth BioTherapeutics Corp
Latest News

Tuesday, 7 May 2024
10:30	STEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION	prnewswire.com
Monday, 6 May 2024
08:00	Stealth BioTherapeutics to Present at JMP Citizens Life Sciences Conference	PRNewsWire
Wednesday, 8 June 2022
15:16	Good Penny Stocks to Buy Today? 3 to Watch Right Now	PennyStocks
09:47	Why Stealth BioTherapeutics Shares Are Surging Today?	Benzinga
Tuesday, 10 May 2022
08:00	What to Know About Buying Penny Stocks on May 10th	PennyStocks
Monday, 2 May 2022
09:25	Stealth Bio Posts Disappointing Elamipretide Data From Mid-Stage Geographic Atrophy Study	Benzinga
Wednesday, 9 March 2022
17:00	Stealth BioTherapeutics to Present at Upcoming March Investor Conferences	PRNewsWire
Tuesday, 22 February 2022
07:30	Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit	PRNewsWire
Tuesday, 4 January 2022
07:30	Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference	PRNewsWire
Thursday, 11 November 2021
13:25	Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
Wednesday, 20 October 2021
09:14	Stealth Bio Stock Falls On FDA Refusal to File Letter For Barth Syndrome Candidate	Benzinga
Thursday, 7 October 2021
17:00	Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting	PRNewsWire
Thursday, 23 September 2021
11:13	Stealth Bio Posts Encouraging Preclinical Data In Parkinson's Animal Studies	Benzinga
07:30	Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at International Parkinson and Movement Disorder Society Virtual Congress 2021	PRNewsWire
Wednesday, 15 September 2021
08:22	MITO Stock: Why It Is Trading Higher	Pulse2
Tuesday, 14 September 2021
07:30	Stealth BioTherapeutics to Showcase Leadership in Retinal Mitochondrial Health with Clinical Updates at Ophthalmic Conferences	PRNewsWire
Tuesday, 7 September 2021
16:30	Stealth BioTherapeutics to Present at Upcoming September Virtual Investor Conferences	PRNewsWire
Wednesday, 25 August 2021
13:06	Stealth (MITO) Files NDA for Ultra-Rare Disease Candidate	Zacks Investment Research
Tuesday, 24 August 2021
09:29	Stealth Bio Files US Application For Ultra Rare Genetic Disease Candidate	Benzinga
07:30	Stealth BioTherapeutics Submits Elamipretide New Drug Application to FDA for Treatment of Barth Syndrome	PRNewsWire
Monday, 23 August 2021
07:30	Stealth BioTherapeutics Strengthens IP Portfolio with Issuance of U.S. Patents Covering Elamipretide for Barth Syndrome	PRNewsWire

Frequently Asked Questions (FAQ)

What's the price of Stealth BioTherapeutics Corp stock today?

One share of Stealth BioTherapeutics Corp stock can currently be purchased for approximately $0.32.
When is Stealth BioTherapeutics Corp's next earnings date?

Unfortunately, Stealth BioTherapeutics Corp's (MITO) next earnings date is currently unknown.
Does Stealth BioTherapeutics Corp pay dividends?

No, Stealth BioTherapeutics Corp does not pay dividends.
What is Stealth BioTherapeutics Corp's stock symbol?

Stealth BioTherapeutics Corp is traded on the NASDAQ under the ticker symbol "MITO".
What is Stealth BioTherapeutics Corp's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Stealth BioTherapeutics Corp?

Shares of Stealth BioTherapeutics Corp can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Stealth BioTherapeutics Corp have?

As Jul 2024, Stealth BioTherapeutics Corp employs 38 workers.
When Stealth BioTherapeutics Corp went public?

Stealth BioTherapeutics Corp is publicly traded company for more then 6 years since IPO on 15 Feb 2019.
What is Stealth BioTherapeutics Corp's official website?

The official website for Stealth BioTherapeutics Corp is stealthbt.com.
Where are Stealth BioTherapeutics Corp's headquarters?

Stealth BioTherapeutics Corp is headquartered at 190 Elgin Avenue, George Town, GEORGE TOWN, GRAND CAYMAN.
How can i contact Stealth BioTherapeutics Corp?

Stealth BioTherapeutics Corp's mailing address is 190 Elgin Avenue, George Town, GEORGE TOWN, GRAND CAYMAN and company can be reached via phone at +61 76006888.

Stealth BioTherapeutics Corp

stealthbt.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

+61 76006888

190 Elgin Avenue, George Town
GEORGE TOWN, GRAND CAYMAN KY1-9005

CIK: 0001696396
ISIN: US85789A1051
CUSIP: 85789A105